NCT07555171Enrolling By Invitation不适用
EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To evaluate the concordance between electroencephalogram (EEG) changes and clinical responsiveness in patients diagnosed with Lennox-Gastaut Syndrome (LGS) undergoing treatment with fenfluramine.
研究概览
简要总结
This study plans to learn if certain markers found during electroencephalogram (EEG) analysis could predict fenfluramine responsiveness to give clinicians greater insight into the effectiveness of fenfluramine in people with Lennox Gastaut Syndrome (LGS).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 2 Years 至 35 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children and adults aged 2 to 35 years
- •Have a confirmed diagnosis of Lennox-Gastaut Syndrome (LGS), validated by the Epilepsy Study Consortium
- •Documented seizure onset at age 11 years or younger, accompanied by multiple seizure types, specifically including tonic seizures and atonic or tonicatonic seizures.
- •Participants must exhibit a stable seizure baseline for at least 4 weeks prior to enrollment, with documented frequency of two or more drop seizures per week, characterized as generalized tonic-clonic (GTC), secondary GTC (focal to bilateral tonic-clonic seizures), tonic, atonic, or combined tonic-atonic seizures.
- •Participants must exhibit abnormal cognitive development and a medical history consistent with electroencephalographic (EEG) findings demonstrating abnormal background activity characterized by a slow spike-andwave pattern at a frequency of less than 2.5 Hz.
- •Participants must have a clearly documented etiology of LGS falling into one of the following categories: structural, genetic, metabolic, infectious, immune or unknown.
- •Participants must have had a valid baseline EEG that reflects their clinical state during a stable seizure period and must have been conducted within 6 months prior to study enrollment.
- •Participants must be currently receiving fenfluramine as part of their clinical management regimen. Fenfluramine dosing must follow established LGS-specific dosing guidelines, initiated at 0.1 mg/kg administered orally twice daily, with weekly dose titration based on tolerability and clinical response until reaching the recommended maintenance dose of 0.35 mg/kg orally twice daily, not exceeding a total daily dose of 26 mg.
- •At the time of enrollment, participants must have been on a stable antiseizure medication (ASM) regimen for at least 30 days, defined as receiving between one and four concomitant ASMs without any recent medication changes, aside from the addition of fenfluramine. To ensure accurate baseline EEG assessments, participants must have a documented EEG recorded within 6 months (±2 months) prior to initiation of fenfluramine treatment.
- •Caregivers or legal guardians must provide informed consent, and participant assent will be obtained when developmentally appropriate according to ethical standards.
排除标准
- •Patients have been diagnosed with any progressive neurodegenerative disorders, as these conditions could confound the interpretation of fenfluramine's clinical efficacy and safety profile.
- •Individuals with a documented history of fenfluramine use prior to obtaining baseline EEG will be excluded to ensure the baseline EEG data accurately represent the pre-treatment neurophysiological state.
- •Participants who have incomplete medical records, inadequate EEG documentation, or insufficient diagnostic workup confirming LGS diagnosis.
结局指标
主要结局
To evaluate the concordance between electroencephalogram (EEG) changes and clinical responsiveness in patients diagnosed with Lennox-Gastaut Syndrome (LGS) undergoing treatment with fenfluramine.
时间窗: from EEG prior to fenfluarmine initiation to follow up EEG 6 months after
次要结局
- To identify and validate specific EEG biomarkers predictive of clinical responsiveness to fenfluramine treatment.(from EEG prior to fenfluarmine initiation to follow up EEG 6 months after)
- To quantitatively assess longitudinal EEG dynamics, including changes in background activity, paroxysmal fast activity, epileptiform discharges, and sleep architecture, before and during fenfluramine therapy.(from EEG prior to fenfluarmine initiation to follow up EEG 6 months after)
- To characterize EEG biomarker differences between clinical responders and non- responders to fenfluramine.(from EEG prior to fenfluramine initiation to follow up EEG 6 months after)
- To evaluate patient- and caregiver-reported changes in epilepsy-specific quality of life associated with fenfluramine treatment using validated instruments.(from prior to EEG initiation to 6 months after)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
Unknown
经颅直流电刺激治疗 Lennox-Gastaut 综合征的初步临床对照观察癫痫ChiCTR180001572320
招募中
Unknown
新靶点经颅直流电刺激治疗 Lennox-Gastaut 综合征的初步临床对照观察癫痫ChiCTR180001572020
尚未招募
3 期
A study to see if adding prednisolone ( a steroid ) helps control seizures in children aged 3–12 years with a difficulty to control seizure disorder called Lennox-Gastaut syndromeCTRI/2025/10/096645Child Neurology Division, AIIMS New Delhi50
招募中
2 期
Effect of adding Memantine to treatment in Lennox Gastaut Syndrome.CTRI/2026/01/100753Professor Jayantee Kalita120
Unknown
不适用
中央中核脑深部电刺激治疗 Lennox–Gastaut 综合征全面性癫痫的疗效与安全性研究ChiCTR2400088309自选课题（自筹）